Pse-T2, an Antimicrobial Peptide with High-Level, Broad-Spectrum Antimicrobial Potency and Skin Biocompatibility against Multidrug-Resistant Pseudomonas aeruginosa Infection

Antimicrob Agents Chemother. 2018 Nov 26;62(12):e01493-18. doi: 10.1128/AAC.01493-18. Print 2018 Dec.

Abstract

Pseudin-2, isolated from the frog Pseudis paradoxa, exhibits potent antibacterial activity but also cytotoxicity. In an effort to develop clinically applicable antimicrobial peptides (AMPs), we designed pseudin-2 analogs with Lys substitutions, resulting in elevated amphipathic α-helical structure and cationicity. In addition, truncated analogs of pseudin-2 and Lys-substituted peptides were synthesized to produce linear 18-residue amphipathic α-helices, which were further investigated for their mechanism and functions. These truncated analogs exhibited higher antimicrobial activity and lower cytotoxicity than pseudin-2. In particular, Pse-T2 showed marked pore formation, permeabilization of the outer/inner bacterial membranes, and DNA binding. Fluorescence spectroscopy and scanning electron microscopy showed that Pse-T2 kills bacterial cells by disrupting membrane integrity. In vivo, wounds infected with multidrug-resistant (MDR) Pseudomonas aeruginosa healed significantly faster when treated with Pse-T2 than did untreated wounds or wounds treated with ciprofloxacin. Moreover, Pse-T2 facilitated infected-wound closure by reducing inflammation through suppression of interleukin-1β (IL-1β), IL-6, and tumor necrosis factor alpha (TNF-α). These data suggest that the small antimicrobial peptide Pse-T2 could be useful for future development of therapeutic agents effective against MDR bacterial strains.

Keywords: antimicrobial peptide; cell selectivity; membrane disruption; multidrug-resistant bacteria; wound closure.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amphibian Proteins / chemical synthesis
  • Amphibian Proteins / pharmacology*
  • Animals
  • Anti-Bacterial Agents / chemical synthesis
  • Anti-Bacterial Agents / pharmacology*
  • Antimicrobial Cationic Peptides / chemical synthesis
  • Antimicrobial Cationic Peptides / pharmacology*
  • Anura
  • Biofilms / drug effects
  • Biofilms / growth & development
  • Cell Membrane / drug effects
  • Cell Membrane / metabolism
  • Ciprofloxacin
  • Drug Resistance, Multiple, Bacterial / drug effects
  • Drug Resistance, Multiple, Bacterial / genetics
  • Escherichia coli / drug effects
  • Escherichia coli / growth & development
  • Interleukin-1beta / antagonists & inhibitors
  • Interleukin-1beta / biosynthesis
  • Interleukin-6 / antagonists & inhibitors
  • Interleukin-6 / biosynthesis
  • Mice
  • Mice, Inbred BALB C
  • Microbial Sensitivity Tests
  • Peptides / chemical synthesis
  • Peptides / pharmacology*
  • Protein Engineering
  • Pseudomonas Infections / drug therapy*
  • Pseudomonas Infections / metabolism
  • Pseudomonas Infections / pathology
  • Pseudomonas aeruginosa / drug effects*
  • Pseudomonas aeruginosa / genetics
  • Pseudomonas aeruginosa / growth & development
  • Skin / drug effects
  • Skin / injuries
  • Skin / metabolism
  • Staphylococcus aureus / drug effects
  • Staphylococcus aureus / growth & development
  • Structure-Activity Relationship
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Tumor Necrosis Factor-alpha / biosynthesis
  • Wound Healing / drug effects
  • Wounds, Nonpenetrating / drug therapy*
  • Wounds, Nonpenetrating / metabolism
  • Wounds, Nonpenetrating / pathology

Substances

  • Amphibian Proteins
  • Anti-Bacterial Agents
  • Antimicrobial Cationic Peptides
  • IL1B protein, mouse
  • Interleukin-1beta
  • Interleukin-6
  • Peptides
  • Tumor Necrosis Factor-alpha
  • interleukin-6, mouse
  • pseudin-2 protein, Pseudis paradoxa
  • Ciprofloxacin